Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.39 -1.0%	$10.40	$3.85 ▼ $12.43	$1.60B	1.83	1.64 million shs	1.44 million shs
ATYR aTyr Pharma	$5.99 +3.5%	$4.76	$1.58 ▼ $6.43	$515.34M	0.89	1.37 million shs	5.07 million shs
CNTA Centessa Pharmaceuticals	$15.69 -1.7%	$13.17	$9.00 ▼ $19.09	$2.13B	1.45	773,725 shs	1.01 million shs
HRMY Harmony Biosciences	$35.20 -3.4%	$33.84	$26.47 ▼ $41.61	$2.09B	0.83	635,644 shs	701,636 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-3.05%	-13.08%	+3.55%	+43.25%	+141.38%
ATYR aTyr Pharma	-0.86%	+8.63%	+12.65%	+86.77%	+242.60%
CNTA Centessa Pharmaceuticals	+1.98%	+8.94%	+26.67%	+29.76%	+67.65%
HRMY Harmony Biosciences	+3.46%	+6.12%	+12.20%	+28.00%	+10.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.7895 of 5 stars	1.4	1.0	4.2	2.7	2.5	0.6
ATYR aTyr Pharma	2.5041 of 5 stars	3.6	1.0	0.0	3.5	1.7	0.6
CNTA Centessa Pharmaceuticals	3.4077 of 5 stars	3.5	4.0	0.0	2.3	3.3	0.6
HRMY Harmony Biosciences	4.801 of 5 stars	4.5	1.0	0.0	3.4	3.3	4.4

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	1.75% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	237.23% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	77.75% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	45.83% Upside

Current Analyst Ratings Breakdown

Latest ATYR, CNTA, HRMY, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.82	N/A	N/A	$1.37 per share	7.58
ATYR aTyr Pharma	$230K	2,317.87	N/A	N/A	$0.83 per share	7.22
CNTA Centessa Pharmaceuticals	$6.85M	305.90	N/A	N/A	$3.05 per share	5.14
HRMY Harmony Biosciences	$714.73M	2.83	$2.85 per share	12.36	$11.56 per share	3.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	0.00	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
ATYR aTyr Pharma	-$64.02M	-$0.81	0.00	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	0.00	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.90	11.32	0.50	20.53%	24.32%	15.92%	8/5/2025 (Estimated)

Latest ATYR, CNTA, HRMY, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
ATYR aTyr Pharma	0.01	7.79	7.79
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
HRMY Harmony Biosciences	0.22	3.67	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ATYR aTyr Pharma	61.72%
CNTA Centessa Pharmaceuticals	82.01%
HRMY Harmony Biosciences	86.23%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ATYR aTyr Pharma	3.70%
CNTA Centessa Pharmaceuticals	7.09%
HRMY Harmony Biosciences	23.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable

ATYR, CNTA, HRMY, and ADPT Headlines

Recent News About These Companies

Edgestream Partners L.P. Takes $2.52 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

July 18 at 4:59 AM | marketbeat.com

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

July 17 at 1:11 PM | zacks.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of "Buy" from Brokerages

July 16 at 2:04 AM | marketbeat.com

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

July 15 at 8:56 PM | msn.com

3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

July 15 at 8:56 PM | msn.com

Mizuho Reaffirms “Outperform” on Harmony Biosciences (HRMY) for BP1.15205 Data

July 15 at 8:56 PM | finance.yahoo.com

3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

July 15 at 1:46 PM | zacks.com

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

July 15 at 12:41 PM | zacks.com

Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?

July 15 at 10:56 AM | zacks.com

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

July 15 at 10:41 AM | zacks.com

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

July 15 at 8:43 AM | businesswire.com

6 Analysts Assess Harmony Biosciences Hldgs: What You Need ... - Benzinga

July 12, 2025 | benzinga.com

Moloney Securities Asset Management LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

July 11, 2025 | marketbeat.com

Harmony Biosciences (NASDAQ:HRMY) Price Target Raised to $55.00 at Deutsche Bank Aktiengesellschaft

July 10, 2025 | marketbeat.com

Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise

July 10, 2025 | msn.com

H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)

July 10, 2025 | finance.yahoo.com

The Goldman Sachs Group Initiates Coverage on Harmony Biosciences (NASDAQ:HRMY)

July 10, 2025 | marketbeat.com

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

July 4, 2025 | zacks.com

First Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq

June 24, 2025 | nasdaq.com

Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)

June 24, 2025 | msn.com

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, CNTA, HRMY, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.39 -0.11 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$10.28 -0.11 (-1.01%)

As of 07:54 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

aTyr Pharma NASDAQ:ATYR

$5.99 +0.20 (+3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$6.16 +0.18 (+2.92%)

As of 07:58 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Centessa Pharmaceuticals NASDAQ:CNTA

$15.69 -0.27 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$16.10 +0.41 (+2.61%)

As of 07:23 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Harmony Biosciences NASDAQ:HRMY

$35.20 -1.23 (-3.38%)

Closing price 04:00 PM Eastern

Extended Trading

$35.48 +0.28 (+0.80%)

As of 07:10 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time